News | June 25, 2007

July 1 Marks the Launch of CMS Physician Quality Reporting Initiative

June 26, 2007 - Physicians who report quality measures for care delivered to Medicare beneficiaries July 1–December 31, 2007 may receive an additional 1.5 percent incentive payment, subject to a bonus payment cap.

Voluntary participants must report a minimum of three quality measures on at least 80 percent of the cases for which that quality measure is reportable. If it is determined that reporting occurred less than 80 percent of the time for any one of the measures, the physician would be ineligible for the incentive payment.

Quality measures within the 2007 Physician Quality Reporting Initiative (PQRI) are adopted or endorsed by a consensus organization such as the AQA Alliance, the Physician Consortium, or National Quality Forum (NQF). HRS' Quality Improvement Task Force, Chaired by Stephen C. Hammill, M.D., and Sana Alkhatib, M.D., has been working on efforts to include reimbursement codes routinely used by HRS Membership into this initiative. 74 quality measures have been announced with specific reimbursement codes linked to each quality measure.

Members of the Heart Rhythm Society have the opportunity to report on:

* ACE or ARB therapy for heart failure patients with Left Ventricular Systolic Dysfunction (LVSD)
* Antiplatelet therapy prescribed for Coronary Artery Disease (CAD) patients
* Beta-blocker therapy prescribed for CAD patients with prior Myocardial Infarction (MI)
* Beta-blocker therapy prescribed for heart failure patients with LVSD
* Perioperative Care: Timing of Antibiotic Prophylaxis – Ordering Physician
* Perioperative Care: Discontinuation of Prophylactic Antibiotic

Reporting is claims-based. CPT Category II codes (or temporary G-codes where CPT Category II codes are not yet available) will be used for reporting quality data. Quality data codes, which supply the measure numerator, must be reported on the same claim as the payment codes, which supply the measure denominator. CMS will provide new information and educational opportunities in the near future.

For more information: www.hrsonline.org.

Related Content

Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Study Discovers Anticoagulant Drugs Are Being Prescribed Against Safety Advice
News | Antiplatelet and Anticoagulation Therapies| July 25, 2017
July 25, 2017 — A study by researchers at the University of Birmingham has shown that general practitioners (GPs) are
long-duration dual anti-platelet therapy (L-DAPT) compared to short-duration dual antiplatelet (S-DAPT) after DES stent implantation
News | Antiplatelet and Anticoagulation Therapies| July 12, 2017
June 12, 2017 — Researchers have evaluated the long-term efficacy and safety of long-duration dual anti-platelet ther
Sex-Specific Cardiovascular Drug Dosages Needed to Reduce Adverse Reactions in Women
News | Womens Healthcare| July 07, 2017
Sex-specific cardiovascular drug dosages are needed to reduce adverse reactions in women, according to a position paper...
Bayer Now Enrolling Patients for Global Pulmonary Arterial Hypertension Study
News | Hypertension| July 05, 2017
Bayer has enrolled the first patient in a global Phase IV study assessing the clinical effects of riociguat in patients...
FDA Grants Priority Review of Xarelto sNDA for 10 mg Dose
News | Antiplatelet and Anticoagulation Therapies| June 29, 2017
Janssen Research & Development LLC announced the U.S. Food and Drug Administration (FDA) accepted for Priority...
radial access, transradial access trial using anticoagulants
News | Radial Access| June 15, 2017
June 15, 2017 — In patients undergoing t...
Cost comparison between NOACs, novel oral anticoagulants
News | Antiplatelet and Anticoagulation Therapies| May 31, 2017
May 31, 2017 – The results from the first real-world, matched head-to-head study comparing all-cause healthcare costs
Data was positive from the Watchman Left Atrial Appendage Closure (LAAC) Device from the EWOLUTION registry
News | Atrial Fibrillation| May 30, 2017
May 30, 2017 — Data was positive for safety and efficacy rates of the Watchman Left Atrial Appendage Closure (LAAC) D
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals| May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Overlay Init